focus -WSS

focus

author：leisure time 2025-09-03 15:23:46 - browse：5534

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Lung cancer is America's deadliest cancer. Yet so few get screened

WSS

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Congress must give Medicare recipients genetic counseling access

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

ActiGraph execs on goal of drug approvals with digital endpoints

Dexcom's push to bring CGM to type 2 diabetes patients

entertainment

focus

entertainment

What does generative AI mean for health care? We asked experts

Listen: Racing for gene therapy & a pioneering approval

Cancer drug shortages should be causing more outrage

Clinical trials must include more disabled people

Cancer drug shortages should be causing more outrage

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Medical leaders decry Supreme Court decision on affirmative action

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

In age of alternative facts, a scholarly course on calling out crap

Living with Hashimoto's and celiac disease, and med school, too

focus

Security flaws in third

Living with Hashimoto's and celiac disease, and med school, too

An interview with Robert F. Kennedy Jr. on vaccines

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Baltimore teen accused of firing into crowd during block party mass shooting

What affirmative action's end means to a medical student

Wikipedia

Wikipedia

entertainment

knowledge